Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Tango Therapeutics, Inc. (TNGX : NSDQ)

• Company Description    Tango Therapeutics Inc. is a biotechnology company. It focused on discovering and delivering precision cancer medicines. Tango Therapeutics Inc., formerly known as BCTG Acquisition Corp., is based in CAMBRIDGE, Mass. Number of Employees: 137

• Price / Volume Information    Yesterday's Closing Price: $22.70 Daily Weekly Monthly 20 Day Moving Average: 1,952,399 shares Shares Outstanding: 168.61 (millions) Market Capitalization: $3,827.46 (millions) Beta: 1.12 52 Week High: $34.39 52 Week Low: $6.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.82% -13.20% 12 Week -29.42% -30.91% Year To Date 156.21% 128.56%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 201 BROOKLINE AVE. SUITE 901 - BOSTON,MA 02215 USA ph: 857-320-4900 fax: - ir@tangotx.com http://www.tangotx.com

• General Corporate Information    Officers Malte Peters - Chief Executive Officer; President and Director Barbara Weber - Executive Chairman Daniella Beckman - Chief Financial Officer Alexis Borisy - Director Lesley Ann Calhoun - Director Peer Information Tango Therapeutics, Inc. (CORR.) Tango Therapeutics, Inc. (RSPI) Tango Therapeutics, Inc. (CGXP) Tango Therapeutics, Inc. (BGEN) Tango Therapeutics, Inc. (GTBP) Tango Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 87583X109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/03/26 Share - Related Items Shares Outstanding: 168.61 Most Recent Split Date: (:1) Beta: 1.12 Market Capitalization: $3,827.46 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.40 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.20 Price/Cash Flow: - Price / Sales: 57.55 EPS Growth vs. Year Ago Period: -5.71% vs. Previous Quarter: -15.63% Sales Growth vs. Year Ago Period: 363.61% vs. Previous Quarter: 1,591.64% ROE 06/30/26 - -25.75 03/31/26 - -41.54 12/31/25 - -50.30 ROA 06/30/26 - -23.36 03/31/26 - -33.44 12/31/25 - -36.25 Current Ratio 06/30/26 - 50.82 03/31/26 - 27.38 12/31/25 - 16.32 Quick Ratio 06/30/26 - 50.82 03/31/26 - 27.38 12/31/25 - 16.32 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - -230.03 03/31/26 - -188.20 12/31/25 - -162.85 Book Value 06/30/26 - 7.08 03/31/26 - 2.71 12/31/25 - 2.57 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©